Novel Developments in Stem Cell Mobilization - Focus on CXCR4 (Paperback, 2012 ed.)

Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.

General

Imprint:	Springer-Verlag New York
Country of origin:	United States
Release date:	April 2014
First published:	2012
Editors:	Stefan Fruehauf • W. Jens Zeller • Gary Calandra
Dimensions:	235 x 155 x 28mm (L x W x T)
Format:	Paperback
Pages:	498
Edition:	2012 ed.
ISBN-13:	978-1-4899-9376-2
Categories:	Books > Medicine > Other branches of medicine > Pharmacology > General Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General Promotions
LSN:	1-4899-9376-2
Barcode:	9781489993762

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!